Open Nav

Nurix, Inc.

  • Arthur Sands, Nurix, Inc.

Investor awareness

  • Date:Wednesday, October 17
  • Time:11:30 AM - 11:45 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Nurix discovers and develops small molecule drugs that control the levels of disease-associated proteins to provide new treatments for unmet medical needs. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our initial focus is on developing drugs as treatments for hematologic cancers and immune-mediated diseases including immune-oncology.
  • Company
  • Company HQ City:San Francisco
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Arthur Sands, M.D., Ph.D.
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Hematology and immune-oncology
  • Development Phase of Primary Product:Pre-Clinical
  • Previous and Current Investors:The Column Group, Third Rock Ventures, Celgene
  • Size of Last Investment Round:$17M
  • Total Amount Raised to Date, In All Rounds:$49M
Arthur Sands
Nurix, Inc.